archiveNovo Nordisk

LONDON,ENGLAND - MAY 30: A photo illustration of a Mounjaro pen on May 30 2025 in London, England. ... More Mounjaro is a treatment for weight loss and type 2 diabetes. (Photo by Peter Dazeley via Getty Images)Peter Dazeley Question: Why would you pay 81 times earnings for AbbVie stock when you can buy LLY for a similar valuation of 76 times earnings? You wouldn’t, especially when you consider three simple facts: Growth: Eli Lilly's growth rate is accelerating at over 30%, dwarfing AbbVie's under 5%. Over the last three...

In this photo illustration, boxes of the diabetes drug Ozempic rest on a pharmacy counter on April 17, 2023 in Los Angeles, California. - Image: Mario Tama / Staff (Getty Images) Big Pharma is expected to see big returns from its investment in a class of drugs made famous by Novo Nordisk’s (NVO) popular diabetes drug Ozempic. Deloitte’s annual report, Measuring the Return from Pharmaceutical Innovation, found that GLP-1 drugs could fuel significant returns on research and development investments made last year by major drugmakers. The consulting firm analyzed the...